Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for OcuMension Therapeutics

    Client Virtual Booth

    OCUMENSION THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    OcuMension Therapeutics
    China Flag
    Country
    Country
    China
    Address
    Address
    Room 502-1, Wangwang Building, No. 211 Shimen 1st Road, Jing'an District, Shanghai
    Telephone
    Telephone
    +86 (021)-61493800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ocumension.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    China approves treatment for chronic non-infectious eye inflammation
    China approves treatment for chronic non-infectious eye inflammation

    https://www.biospectrumasia.com/news/25/20560/china-approves-treatment-for-chronic-non-infectious-eye-inflammation.html

    BIOSPECTRUMASIA
    23 Jun 2022
    Share Share
    In a first, China approves eye implant based solely on RWD
    In a first, China approves eye implant based solely on RWD

    https://www.fiercepharma.com/pharma/first-china-approves-eye-implant-based-solely-real-world-data

    Nick Paul Taylor FIERCEPHARMA
    22 Jun 2022
    Share Share
    Ocumension Therapeutics Announces 2021 Interim Results
    Ocumension Therapeutics Announces 2021 Interim Results

    https://www.prnewswire.com/news-releases/ocumension-therapeutics-announces-2021-interim-results-301359820.html

    PRNEWSWIRE
    20 Aug 2021
    Share Share
    Alimera Sciences Receives $20 Million From Ocumension Therapeutics
    Alimera Sciences Receives $20 Million From Ocumension Therapeutics

    https://www.globenewswire.com/news-release/2021/04/14/2210059/0/en/Alimera-Sciences-Receives-20-Million-From-Ocumension-Therapeutics.html

    GLOBENEWSWIRE
    14 Apr 2021
    Share Share
    Ocumension Therapeutics invests $15.7 million in EyePoint Pharmaceuticals
    Ocumension Therapeutics invests $15.7 million in EyePoint Pharmaceuticals

    http://www.pharmabiz.com/NewsDetails.aspx?aid=134570&sid=2

    PHARMABIZ
    04 Jan 2021
    Share Share
    Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases
    Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases

    https://pipelinereview.com/index.php/2020110276367/Antibodies/Ocumension-Therapeutics-Strengthens-Pipeline-for-Posterior-Segment-Eye-Diseases.html

    PIPELINEREVIEW
    02 Nov 2020
    Share Share
    Ocumension strengthens pipeline for posterior segment eye diseases in China
    Ocumension strengthens pipeline for posterior segment eye diseases in China

    https://www.biospectrumasia.com/news/98/17026/ocumension-strengthens-pipeline-for-posterior-segment-eye-diseases-in-china.html

    BIOSPECTRUMASIA
    30 Oct 2020
    Share Share
    Ocumension strengthens pipeline for posterior segment eye diseases in China
    Ocumension strengthens pipeline for posterior segment eye diseases in China

    https://www.biospectrumasia.com/news/98/17026/ocumension-strengthens-pipeline-for-posterior-segment-eye-diseases-in-china.html

    BIOSPECTRUMASIA
    30 Oct 2020
    Share Share
    Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Trial
    Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Trial

    https://www.globenewswire.com/news-release/2020/09/23/2098185/0/en/Nicox-Selects-0-1-NCX-470-Dose-in-Adaptive-Stage-of-Mont-Blanc-Phase-3-Glaucoma-Trial.html

    GLOBENEWSWIRE
    23 Sep 2020
    Share Share
    EyePoint Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics
    EyePoint Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics

    https://www.globenewswire.com/news-release/2020/08/20/2081211/0/en/EyePoint-Pharmaceuticals-Receives-9-5-Million-in-Upfront-Cash-from-Ocumension-Therapeutics-Under-Expanded-License-Agreements.html

    GLOBENEWSWIRE
    20 Aug 2020
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search